Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HB0V
|
|||
| Former ID |
DNCL002524
|
|||
| Drug Name |
JX-594
|
|||
| Synonyms |
Pexastimogene devacirepvec
Click to Show/Hide
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1], [2], [3] | |
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [4] | ||
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 2 | [4] | ||
| Company |
Jennerex Biotherapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health. | |||
| REF 5 | Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.